Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor

Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor

Dual inhibitor of topoisomerase 1 and 2, inducing G(2) arrest in the absence of DNA damage. Inhibitor of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay

Novel inhibitor of the heterogeneous ribonuclear protein A18 (hnRNP A18)

Novel blocker of IL-17A binding to the IL-17A receptor (IL-17RA)

Novel activator of cellular ATG4B activity

Potent natural modulator of human Toll-like receptor 7 (TLR7)

Metablite of the Streptomyces antibiotics streptothricin and streptolin

Antibiotic, being used as an antineoplastic agent and to induce diabetes in experimental animals

The first nonpeptidyl, selective activator of the tissue-protective EPOR/CD131 receptor

Novel agonist of the tissue-protective erythropoietin (EPO) receptor, increasing FXN expression and EPOR phosphorylation

Inhibitor of 17β-hydroxysteroid dehydrogenases (17β-HSDs)

Novel Nonsteroidal Inhibitor of Carbonic Anhydrase IX

Novel dual Inhibitor of repair enzymes 8-oxoguanine DNA glycosylase (OGG1) and human MutT Homolog 1 (NUDT1 or MTH1), increasing sensitivity of tumor cells to oxidative stress

Novel potent c-MET inhibitor

Potent c-MET inhibitor

Sunitinib analog, acting as a potential inhibitor for nucleoside diphosphate kinase (NDK) from Leishmania major (LmNDK)

Agonist of TRPV1

Novel potent and selective inhibitor of the cellular PDGF receptor kinase and PDGF receptor-induced cell proliferation

Natural immunosuppressive agent, effectively blocking T cell proliferation and survival while profoundly inhibiting pro-inflammatory IFNγ and IL-17 production by fully differentiated effector Th1 and Th17 cells, also acting as an estrogen receptor antagon

Fluorescent substrate which can be hydrolyzed by the proteasome to release free AMC and the fluorescence of which is proportional to the proteasome activity

Novel antagonist of G-protein-coupled receptor SUCNR1 (succinate receptor 1 or GPR91)